Here are 1-3 brief analogies for Vaxcyte (PCVX):

• Imagine a clinical-stage Pfizer or Merck that solely develops next-generation bacterial protein vaccines.
• Like an early Moderna or BioNTech, but focused on pioneering new protein vaccines for bacterial diseases rather than mRNA.

• VAX-24: A 24-valent investigational pneumococcal conjugate vaccine in Phase 1/2 clinical trials for invasive pneumococcal disease and pneumonia.
• VAX-XP: A vaccine candidate aimed at protecting against emerging bacterial strains and combating antibiotic resistance.
• VAX-A1: A conjugate vaccine candidate being developed to treat Group A Strep infections.
• VAX-PG: A novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis.

Major Customers of Vaxcyte (PCVX)

Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing novel protein vaccines. As its lead vaccine candidate, VAX-24, and other pipeline candidates are currently in Phase 1/2 clinical trials and have not yet received regulatory approval for commercial sale, the company does not currently have major commercial customers for its products.

Grant Pickering, MBA Chief Executive Officer, Director and Co-Founder

Grant Pickering co-founded Vaxcyte (formerly SutroVax, Inc.) in 2013 and brings over 30 years of experience in vaccine and immunotherapeutic drug development and commercialization. He has a track record of successfully forming and financing multiple platform companies. Prior to Vaxcyte, Mr. Pickering served as CEO of Mymetics Corporation, a European-based vaccine company. He was also an executive-in-residence at Kleiner, Perkins, Caufield & Byers and CEO at Juvaris BioTherapeutics. He played a significant role in Dendreon Corporation's IPO and led clinical development, operations, and business development, which led to the launch of Provenge®. Additionally, he led marketing and business development for Algos Pharmaceutical Corporation, which was acquired by Endo Pharmaceuticals.

Andrew Guggenhime, MBA President and Chief Financial Officer

Andrew Guggenhime has over 30 years of experience in the biotech and financial services industries, with broad expertise in strategy, finance, operations, investor relations, and corporate development. He joined Vaxcyte in May 2020 as CFO and COO, and was promoted to President and CFO in January 2021. He was instrumental in leading Vaxcyte's IPO in June 2020 and subsequent equity financings. Before joining Vaxcyte, he served as Chief Financial Officer of Dermira, Inc. through its acquisition by Eli Lilly and Company. His previous CFO roles include CardioDx, Inc. (a privately held company), Calistoga Pharmaceuticals, Inc. (acquired by Gilead Sciences, Inc.), Facet Biotech Corporation (acquired by Abbott Laboratories), PDL BioPharma, Inc., and Neoforma, Inc. (acquired by Global Healthcare Exchange, LLC).

Jim Wassil, MS, MBA Executive Vice President and Chief Operating Officer

Jim Wassil has over three decades of extensive experience in developing and commercializing vaccines globally, having held significant leadership positions in the vaccine divisions of Pfizer, Novartis, and Merck. Before joining Vaxcyte in 2019, he was the business unit lead for Pfizer Vaccines, where he was responsible for market access, policy, pricing, tender negotiations, epidemiology, and health outcomes for the entire portfolio, including the pneumococcal conjugate vaccine franchise (Prevnar 13®). At Novartis, he led the development and launch of Menveo, Bexsero®, and the meningococcal ABCWY vaccine candidate. He also led international marketing for the pediatric vaccine franchise at Merck Vaccines, where he launched RotaTeq®.

Mike Mullette, MBA Chief Commercial Officer

Mike Mullette has extensive experience in commercial leadership within the pharmaceutical and biotech industries. Prior to Vaxcyte, he served as Chief Operating Officer and interim Chief Executive Officer of Lykos Therapeutics. Before Lykos, he was Vice President and Managing Director of Commercial Operations for North America at Moderna, leading the global launch and commercialization of the company's COVID-19 vaccine. He also spent nearly two decades at Sanofi in various commercial leadership roles, overseeing a broad portfolio of vaccine products and multiple pediatric and adult vaccine launches across international markets, including Menactra (meningococcal).

Chris Griffith, MS, MBA Chief Business and Strategy Officer

Chris Griffith brings over 20 years of experience in the biopharmaceutical industry, with expertise in corporate development, strategy, and operations. Before joining Vaxcyte, he served as President and CEO of Adanate. He also co-founded and served as Chief Business and Strategy Officer of Dermira, a company that identified, developed, and commercialized immunology and dermatology products, which was acquired by Eli Lilly.

Risk of Clinical Trial Failure and Regulatory Approval

As a clinical-stage biotechnology company, Vaxcyte's primary risk lies in the success or failure of its vaccine candidates in clinical trials and the subsequent ability to obtain regulatory approval. The company's lead candidate, VAX-24, is currently in Phase 1/2 clinical trials, and other candidates like VAX-XP, VAX-A1, and VAX-PG are in earlier stages of development. There is no guarantee that any of these candidates will prove safe and effective, successfully complete all required clinical trials, or receive necessary regulatory approvals from health authorities. Failure to meet these milestones would significantly impact the company's value and future prospects.

Competition in the Vaccine Market

Vaxcyte operates in a highly competitive vaccine market. Even if its vaccine candidates prove successful in clinical trials and receive regulatory approval, they will face competition from existing vaccines marketed by established pharmaceutical companies, as well as new vaccines under development by other biotechnology firms. The ability to differentiate its products, demonstrate superior efficacy or safety, and achieve market adoption against entrenched competitors is a significant challenge for Vaxcyte.

Reliance on Future Funding

As a company without any approved products generating revenue, Vaxcyte is dependent on its ability to raise additional capital to fund its ongoing and future research and development activities, including extensive and costly clinical trials. The company's operations are capital-intensive, and there is no assurance that Vaxcyte will be able to obtain sufficient financing on favorable terms, or at all, when needed. A lack of adequate funding could force the company to delay, scale back, or discontinue some or all of its product development programs.

Vaxcyte (symbol: PCVX) is developing vaccines for several bacterial infectious diseases. The addressable markets for its main product candidates are as follows:

VAX-24 and VAX-XP (Pneumococcal Conjugate Vaccines)

VAX-24 and VAX-XP are pneumococcal conjugate vaccine (PCV) candidates designed to prevent invasive pneumococcal disease and pneumonia.

• The global pneumococcal vaccine market was valued at approximately USD 8.8 billion in 2024 and is projected to reach USD 15.1 billion by 2034.
• Another estimate places the global pneumococcal vaccine market size at USD 8.07 billion in 2023, with a projection to reach USD 12.19 billion by 2030.
• Vaxcyte's market potential within the pneumococcal vaccine market is driven by a total addressable market (TAM) of USD 13.3 billion by 2033.
• The United States alone represents an estimated 45% of the global pneumococcal vaccine market, which was nearly USD 9 billion in 2024.
• The 7 major invasive pneumococcal disease markets (US, EU4, UK, and Japan) reached a value of USD 6.6 billion in 2024 and are expected to grow to USD 12.0 billion by 2035.

VAX-A1 (Group A Strep Conjugate Vaccine)

VAX-A1 is a conjugate vaccine candidate designed to treat Group A Strep (GAS).

• Group A Streptococcus infections result in over 600 million new global cases of pharyngitis per year.
• The annual economic burden of invasive and noninvasive Group A Strep diseases in the U.S. was estimated at USD 6.08 billion.
• Research suggests there is a viable global commercial market for a Strep A vaccine.

VAX-PG (Periodontitis Vaccine)

VAX-PG is a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis.

• The global periodontal therapeutics market (which would encompass a periodontitis vaccine) was valued at approximately USD 927.13 million in 2024 and is expected to reach USD 1.79 billion by 2034.
• Other estimates for the global periodontal therapeutics market include a value of USD 683.97 million in 2025, projected to reach USD 1.31 billion by 2032.
• The U.S. periodontal therapeutics market alone was valued at USD 246.62 million in 2023 and is projected to reach USD 471.30 million by 2032.

Here are 3-5 expected drivers of future revenue growth for Vaxcyte (PCVX) over the next 2-3 years:

1. Advancement of VAX-31 through pivotal Phase 3 clinical trials and subsequent Biologics License Application (BLA) submission for adults: Vaxcyte's lead candidate, VAX-31, a 31-valent pneumococcal conjugate vaccine, is in Phase 3 adult clinical trials, with topline data from the pivotal non-inferiority study (OPUS-1) expected in the fourth quarter of 2026. Multiple additional Phase 3 adult program data readouts are anticipated throughout 2026 and 2027, which are critical milestones supporting a potential BLA submission. Successful progression and regulatory approval are essential for commercial launch, which analysts project around 2028.
2. Positive clinical trial results for VAX-31 in the infant population: Beyond its adult indication, VAX-31 is also being developed for infants. The Phase 2 dose-finding study in infants has completed enrollment, and topline data is expected in the first half of 2027. Favorable results in this significant demographic could expand the vaccine's market potential and accelerate future revenue generation from both adult and pediatric populations.
3. Expansion of manufacturing capabilities in preparation for commercialization: Vaxcyte has been investing significantly in building a dedicated large-scale manufacturing facility, with completion expected by early 2026. This strategic investment in infrastructure is crucial for supporting the anticipated global commercial demand for its pneumococcal conjugate vaccine (PCV) programs once approved, directly enabling future revenue at scale.
4. Pipeline diversification with the advancement of VAX-A1: Vaxcyte plans to initiate a Phase 1 adult study for VAX-A1, a conjugate vaccine candidate designed to prevent Group A Strep infections, in 2026. Progress with VAX-A1 would signify successful pipeline diversification beyond pneumococcal vaccines, laying the groundwork for a broader product portfolio and additional revenue streams in the future.
5. Favorable market dynamics and potential for VAX-31 to become a new standard of care: The pneumococcal vaccine market, particularly the adult segment, is projected to grow significantly, with estimates suggesting an increase to nearly $13 billion by 2027. The recent recommendation for universal PCV vaccination for adults aged 50 and above further expands the target market. VAX-31's design to cover a broad spectrum of 31 pneumococcal strains (potentially 95% of invasive pneumococcal disease in U.S. adults 50+) positions it as a potential best-in-class vaccine, which, upon approval, could capture substantial market share and drive significant revenue growth.

Share Issuance

• In February 2026, Vaxcyte closed an underwritten public offering, raising $632.5 million in gross proceeds through the sale of 12,650,000 shares of common stock at $50.00 per share, which included the full exercise of the underwriters' option to purchase additional shares. This resulted in approximately $600.2 million in net proceeds.
• In February 2026, the company completed a follow-on equity offering, raising approximately $408.1 million.
• Vaxcyte launched a new at-the-market (ATM) program in February 2026, allowing it to sell up to $500 million of common stock, replacing a prior ATM agreement. Under the previous ATM agreement, which was in effect from July 1, 2021, and amended on February 27, 2023, the company sold approximately $270.3 million of common stock before its termination on February 24, 2026.

Capital Expenditures

• As of December 31, 2025, Vaxcyte had incurred $335.4 million in total capital and facility buildout expenditures, primarily related to the dedicated commercial manufacturing suite at Lonza. The buildout of this facility was completed in the first quarter of 2026, staying within the original projected budget of up to $350 million.
• The company incurred $23.0 million in capital expenditures during the third quarter of 2025 for the manufacturing suite at Lonza. An additional $44.6 million was incurred in the second quarter of 2025 for this facility.
• Vaxcyte has initiated the buildout of a high-volume, custom fill-finish line in North Carolina, as part of a long-term commitment of up to $1 billion in U.S. manufacturing and services.